The effect of body weight on dalteparin pharmacokinetics. A preliminary study

European Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2000, Pages 293-297

  Yee, J Y V ^a   Duffull, S B ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Dalteparin; Low molecular weight heparins; Pharmacokinetics

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; LEAN BODY WEIGHT; MALE; OBESITY; PRIORITY JOURNAL;

ANTICOAGULANTS; BAYES THEOREM; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CASE-CONTROL STUDIES; CREATININE; DALTEPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS;

EID: 0033926129     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000141     Document Type: Article

References (26)

1. 1. Herfindal ET, Gourley D (1996) Textbook of therapeutics: drug and disease management. Williams and Wilkins, Baltimore
2. 2. Verstraete M (1990) Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40: 498-530
3. 3. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62: 940-944
4. 4. Koller M, Schoch U, Buchmann P, Largiader F, Von Felten A, Frick PG (1986) Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomised, double-blind study versus unfractionated heparin. Thromb Haemost 56: 243-246
5. 5. Bergqvist D, Burmark US, Frisell J, Lindblad B, Risberg B, Torngren S, Walling G (1986) Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 73: 204-208
6. 6. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Yanson Y, Tissot E (1988) Low molecular weight heparin compared with unfractionated heparin in prevention of post-operative thrombosis. Br J Surg 75: 128-131
7. 7. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M (1987b) A randomised controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315: 925-929
8. 8. Le Balc'h T, Landais A, Butel J, Weill D, Pascariello JC, Planes A (1987) Enoxaparin (Lovenox), versus standard heparin in prophylaxis of deep vein thrombosis after total hip replacement. Thromb Haemost 1[suppl]: 892a
9. 9. Estes JW (1975) The fate of heparin in the body. Curr Ther Res 8: 47-57
10. 10. Andrassy K, Eschenfelder V (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 81: S29-S38
11. 11. Janvier G, Freyburger G, Winnock S, Dugrais G, Boisseau M, Boisserias P (1991) An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg. Haemostasis 21: 161-168
12. 12. Walker R, Edwards C (1994) Clinical pharmacy and therapeutics. Churchill Livingstone, London
13. 13. Devine BJ (1974) Case study number 25 gentamicin therapy. DICP 8: 650-655
14. 14. Bauer LA, Edwards WAD, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24: 643-647
15. 15. Bratt G, Tornebohm E, Widlund L, Lockner D (1986) Low molecular weight heparin (Kabi 2165; Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 42: 613-620
16. 16. Cockroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
17. 17. Pesola GR, Akhavan I, Madu A, Shah NK, Carlon GC (1993) Prediction equation estimates of creatinine clearance in the intensive care unit. Intensive Care Med 19: 39-43
18. 18. Simonneau G, Bergmann JF, Kher A, Soria C, Tobelem G (1992) Pharmacokinetics of a low molecular weight heparin (FRAGMIN) in young and elderly subjects. Thromb Res 66: 603-607
19. 19. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73: 630-640
20. 20. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U (1986) Neutralisation of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 261: 3980
21. 21. Dawes J, Pavuk N (1991) Sequestration of therapeutic glycosaminoglycans by plasma fibronectin (abstract). Thromb Haemost 65: 829
22. 22. Morse WI, Soeldner JS (1963) The composition of adipose tissue and the non adipose body of obese and non obese man. Metab Clin Exp 12: 99-107
23. 23. Stiekema JCJ, Van Giensven JM, Van Dinther TH, Cohen AF (1989) A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminocuronan. Br J Clin Pharmacol 36: 51-56
24. 24. Teien AN, Lie M (1977) Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified anti-thrombin III. Thromb Res 10: 399
25. 25. Dryski M, Schneider DE, Mojaverian P, Kuo BS, Bjornsson TD (1989) Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. Br J Clin Pharmacol 28: 188-192
26. 26. Bratt G, Tornebohm E, Lockner D, Bergstrom K (1985) A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 84: 208-211